Keynote & Exhibit Pass

Keynote & Exhibit Pass offers you access to:

  • 10 PLENARY KEYNOTE PRESENTATIONS
  • KEYNOTE PANEL DISCUSSION – WOMEN IN SCIENCE
  • KEYNOTE PANEL DISCUSSION: IMPLEMENTING PRECISION MEDICINE AT BIG PHARMA

TUESDAY, FEBRUARY 16

PLENARY KEYNOTE SESSION

POWER OF COLLABORATION IN PANDEMIC RESPONSE: ADVANCING COVID-19 MOLECULAR DIAGNOSTICS, VACCINES & BIOTHERAPEUTICS

10:55 am FDA Update on COVID-19 Molecular Diagnostic Testing
Timothy StenzelTimothy Stenzel, MD, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA


11:20 RADx Tech: A New Paradigm for MedTech Development
Steven SchachterSteven Schachter, MD, Professor, Neurology, Harvard Medical School; Chief Academic Officer and RADx Chief, CIMIT


11:45 From Influenza, to Ebola to Zika: How a Decade of Experience and Investments Prepared Us to Respond to This Pandemic
Robert A. JohnsonRobert A. Johnson, PhD, Influenza Director, Biomedical Advanced R&D Authority, US Department of Health & Human Services


12:05 Sponsored Presentation
Speaker to be Announced

12:10 Global Public Health Consortium: A Path for Global Biosecurity through Equity and Transparency
W. Ian LipkinW. Ian Lipkin, MD, Director, Center for Infection and Immunity, Columbia University


WEDNESDAY, FEBRUARY 17

KEYNOTE PANEL DISCUSSION: WOMEN IN SCIENCE

10:30 am Women in Science

Panelists:

Hanneke SchuitemakerHanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center


Carolyn ComptonCarolyn Compton, MD, PhD, FCAP, Professor, Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Mayo College of Medicine; CMO, National Biomarker Development Alliance


Malileh PoorfarhaniMalileh Poorfarhani, Director, Digital Health and R&D, Bayer


PLENARY KEYNOTE SESSION

BIG PHARMA'S RESPONSE TO COVID-19: RAPID DEVELOPMENT OF VACCINES AND BIOTHERAPEUTICS

1:20 pm Exploring New Therapies for COVID-19: Focus on AstraZeneca’s Long-Acting Monoclonal Antibody Combination
Mark T. EsserMark T. Esser, PhD, Vice President, Microbial Sciences, BioPharma R&D, AstraZeneca


1:45 Janssen’s Efforts in the Development of a COVID-19 Vaccine
Hanneke SchuitemakerHanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center


2:10 Developing a COVID Vaccine in Ten Months
Sanjay GurunathanSanjay Gurunathan, MD, Vice President and Head, Global Clinical Department, Sanofi Pasteur


THURSDAY, FEBRUARY 18

PLENARY KEYNOTE SESSION

PRECISION MEDICINE AT BIG PHARMA

11:40 am Turning Science into Medicine: The Power of Collaboration
Mene N. PangalosMene N. Pangalos, PhD, Executive Vice President Biopharmaceuticals R&D, AstraZeneca


12:05 Talk Title to be Announced
Hakan SakulHakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer


12:40 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma

Moderator:
Cecilia Schott, PharmDCecilia Schott, PharmD, MBA, Head, Global Precision Medicine Strategy, Oncology Business Unit, Novartis


Panelists:

Hakan SakulHakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer


Maria C. M. OrrMaria C. M. Orr, PhD, FRSB, Head of Precision Medicine, Biopharmaceuticals, AstraZeneca


Technology Presentations

Clinical Trial Assay & CDx Development in the era of Precision Medicine – Planning for Success
Katarina Wikstrom, PhD, Head of US Operations, Almac Group


SARS-CoV-2 Diagnostics by NGS: Interesting Challenges and Scalable Solutions
Jeremy Ellis, PhD, CSO, Fry Laboratories, LLC


Transforming COVID-19 Testing Through BGI/MGI Clinical Lab Partnership Program
Charles Bao, General Manager, BGI Americas


Exosome-Based Digital PCR for FGFR Assessment in Bladder Cancer
Ronny Kellner, Senior Scientist, dPCR Assay Development, dPCR Assay Development, Qiagen


Clinical Development of a Liquid Biopsy Platform to Aid in the Diagnosis and Treatment of Lung Cancer
Robert J. Mattaliano, PhD, COO, Sanmed Diagnostics Inc.


A Single-Stranded NGS Approach to cfDNA Precision Oncology for Improved Fragmentomic Analyses
Varsha Rao, Director, Clinical R&D, Claret Bioscience LLC


Rapid Analytics for Coronavirus Vaccines using the VaxArray Platform
Erica Dawson, PhD, Chief Technical Officer, InDevR


Transforming Surveillance into Analytics for Predictive Biomarkers and Clinical Diagnostics in Oncology
Mark Gramling, PhD, Director of Oncology, Larvol


Development and Commercialization of a Novel High-Throughput CRISPR-Based SARS-CoV-2 Test
Xin Miao, PhD, Director Assay Development, Mammoth Biosciences
Tim Patno, VP, Product Development, Mammoth Biosciences


Profiling Exhausted T Cells using Vectra® Polaris™ Multiplex Immunofluorescence Assay in HNSCC
Sara Pollan, PhD, Scientist, Multiplexing, NeoGenomics Laboratories


NGS Liquid Biopsy Testing for Solid Tumors: Clinical Trials and Routine Diagnostics
James Yen, PhD, Principal Scientist, Associate Scientific Director, Pharma Services, NeoGenomics Laboratories


A Rapid Lateral Flow Test Detecting SARS-CoV-2 Neutralizing Antibodies
Jianfu Wang, PhD, CEO, Innovation, Novodiax Inc.


 


Advancing Highly Multiplexed Liquid and Tissue Biopsy: Introducing RareCyte’s Orion Platform
Tad George, PhD, Sr. VP of Biology R&D, R&D, RareCyte, Inc.


The SomaScan® Assay: Biomarker Discovery to Delivery
Sheri Wilcox, PhD, Senior Director, Scientific Liaison and Technical Support, SomaLogic, Inc.


New Platform for Liquid Biopsy Enables Precise Cancer Diagnosis and CTC Clusters Detection in Early-Stage Breast Cancer
Roberta Carbone, PhD, CSO, Tethis S.p.A


How Biospecimen Sourcing Can Impact Your R&D Programs
Vanessa Tumilasci, PhD, Commercial Director, Trans-Hit Biomarkers



Premier Sponsors

10x-genomics-logo

Burning-Rock-Dx

NeoGenomics

PrecisionForMedicine_NoTagline



RareCyte

Seegene